Edwards Lifesciences Corporation Stock

Equities

EW

US28176E1082

Advanced Medical Equipment & Technology

Market Closed - Nyse 04:00:02 2024-06-06 pm EDT 5-day change 1st Jan Change
87.68 USD +0.70% Intraday chart for Edwards Lifesciences Corporation -0.24% +14.99%
Sales 2024 * 6.56B Sales 2025 * 7.2B Capitalization 52.84B
Net income 2024 * 1.61B Net income 2025 * 1.86B EV / Sales 2024 * 7.8 x
Net cash position 2024 * 1.7B Net cash position 2025 * 2.84B EV / Sales 2025 * 6.94 x
P/E ratio 2024 *
33.2 x
P/E ratio 2025 *
28.5 x
Employees 19,800
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.59%
More Fundamentals * Assessed data
Dynamic Chart
Edwards Lifesciences Announces Results from Analysis of Data from Partner Trials Examining Outcomes of Transcatheter Aortic Valve Replacement Patients with Small Annulus CI
Transcript : Edwards Lifesciences Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 10:30 AM
Transcript : Edwards Lifesciences Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 12:00 PM
Sector Update: Health Care Stocks Steady Premarket Monday MT
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Division for $4.2 Billion in Cash MT
Edwards Lifesciences to sell critical care products unit to Becton Dickinson for $4.2 bln RE
Becton, Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion MT
Becton, Dickinson and Company entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion. CI
Some of the biggest splits in Corporate America RE
Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 MT
Deutsche Bank Upgrades Edwards Lifesciences to Buy From Hold, Raises Price Target to $103 From $86 MT
Edwards Lifesciences Insider Sold Shares Worth $439,038, According to a Recent SEC Filing MT
Edwards Lifesciences Faces EU Antitrust Complaint By Meril MT
Edwards Lifesciences hit with Meril's EU antitrust complaint RE
Edwards Lifesciences Corporation Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability CI
More news
1 day+0.70%
1 week-0.24%
Current month+0.91%
1 month+3.04%
3 months-0.74%
6 months+26.18%
Current year+14.99%
More quotes
1 week
86.41
Extreme 86.405
88.86
1 month
84.67
Extreme 84.67
91.94
Current year
71.67
Extreme 71.67
96.12
1 year
60.57
Extreme 60.57
96.12
3 years
60.57
Extreme 60.57
131.73
5 years
51.51
Extreme 51.5067
131.73
10 years
13.02
Extreme 13.02
131.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 14-12-31
Director of Finance/CFO 57 13-12-31
Chief Tech/Sci/R&D Officer - 19-01-31
Members of the board TitleAgeSince
Director/Board Member 63 16-07-04
Chairman 67 14-11-12
Director/Board Member 72 16-03-15
More insiders
Date Price Change Volume
24-06-06 87.68 +0.70% 1,680,361
24-06-05 87.07 -0.39% 1,712,914
24-06-04 87.41 -0.51% 1,825,440
24-06-03 87.86 +1.12% 2,658,162
24-05-31 86.89 -1.14% 4,619,581

Delayed Quote Nyse, June 06, 2024 at 04:00 pm EDT

More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows: - heart valves and surgery products (67.9%); - hemodynamic monitoring systems (15.5%); - other (16.6%): balloon catheters, artificial implants, etc. Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.68 USD
Average target price
96.31 USD
Spread / Average Target
+9.84%
Consensus